



Nyrada Annual General Meeting Results

Sydney, 21 November 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, announces the results of today’s Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of a poll.

- ENDS -

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by David Franks, Company Secretary, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize, Investor Relations Manager

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: cstrong@citadelmagnus.com



Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Disclosure of Proxy Votes

Nyrada Inc

Annual General Meeting

Monday, 21 November 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Re-election of John Moore as Director	P	54,856,618	53,058,618 96.72%	0 0.00%	26,897	1,798,000 3.28%	57,331,065 100.00%	0 0.00%	26,897
2 Re-election of Christopher Cox as Director	P	54,835,919	53,037,919 96.72%	0 0.00%	46,897	1,798,000 3.28%	57,310,366 100.00%	0 0.00%	46,897
3 Re-election of Dr. Ian Dixon as Director	P	44,519,386	42,721,386 95.96%	0 0.00%	10,363,430	1,798,000 4.04%	47,196,333 100.00%	0 0.00%	10,160,930
4 Re-election of Marcus Frampton as Director	P	54,664,844	52,846,844 96.67%	0 0.00%	217,972	1,818,000 3.33%	57,139,291 100.00%	0 0.00%	217,972
5 Re-election of Dr. Rüdiger Weseloh as Director	P	54,749,919	52,931,919 96.68%	0 0.00%	132,897	1,818,000 3.32%	57,224,366 100.00%	0 0.00%	132,897
6 Election of Gisela Mautner as Director	P	51,962,585	50,164,585 96.54%	0 0.00%	2,920,231	1,798,000 3.46%	54,437,032 100.00%	0 0.00%	2,920,231
7 Adoption of Equity Incentive Plan	P	42,107,976	40,156,079 95.36%	133,897 0.32%	10,681,341	1,818,000 4.32%	44,448,526 99.70%	133,897 0.30%	10,681,341



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	54,665,741	52,623,844 96.26%	243,897 0.45%	217,075	1,798,000 3.29%	56,896,291 99.57%	243,897 0.43%	217,075

